Related Experiment Video
Updated: Jul 4, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
[Diabetes mellitus and heart failure: epidemiology and therapy]
Roman Pfister1, Erland Erdmann
1Klinik III für Innere Medizin, Herzzentrum der Universität zu Köln, Kerpener Strasse 62, 50937, Köln. roman.pfister@uk-koeln.de
Insights
Managing diabetes mellitus in heart failure patients lacks prospective studies. Current evidence suggests insulin sensitizers may benefit, while insulin and sulfonylureas might be detrimental for these complex patients.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Diseases
Context:
- Diabetes mellitus and heart failure frequently coexist, negatively impacting each other's pathogenesis and prognosis.
- Existing research lacks prospective trials for specific therapies in diabetic heart failure patients.
- The impact of glycemic control on heart failure progression remains unproven.
Purpose:
- To review the current evidence regarding antidiabetic therapies in patients with heart failure.
- To identify potential therapeutic strategies based on retrospective data.
- To highlight the need for prospective, evidence-based treatment guidelines.
Summary:
- Retrospective analyses suggest insulin sensitizers (metformin, glitazones) may have a positive effect in diabetic heart failure.
- Insulin and sulfonylureas appear to have neutral or negative effects in this patient population.
- No definitive, evidence-based antidiabetic therapy is currently recommended for diabetic heart failure.
Impact:
- Highlights a critical gap in clinical guidelines for managing comorbid diabetes and heart failure.
- Informs future research directions for optimizing treatment in this high-risk group.
- Emphasizes the need for prospective, controlled trials to establish evidence-based recommendations.
Abstract:
Diabetes mellitus and heart failure show a high coincidence, promote pathogenesis and worsen prognosis of each other. Currently, there are no prospective studies evaluating a specific antidiabetic or cardiologic therapy in diabetic patients with heart failure. Furthermore, a favorable effect of optimized glycemic control on the progression of heart failure has not been proven yet. Retrospective analyses indicate a rather positive effect of the insulin sensitizers metformin and glitazones and a neutral or rather negative effect of insulin and sulfonylureas in diabetic patients with heart failure. Up to now, due to missing prospective, controlled trials no evidence-based antidiabetic therapy can be recommended in diabetic heart failure patients.
Related Concept Videos
Heart Failure I: Introduction
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure VII: Nursing Interventions
Pathophysiology of Heart Failure